Argenx Se (ARGX) Retained Earnings (2015 - 2026)
Argenx Se's (ARGX) quarterly Retained Earnings came in at $1.4 billion in Q2 2026, up 100.12% YoY from $702.6 million in Q2 2025, and up 10.71% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Retained Earnings (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Retained Earnings data on file, last reported at $1.4 billion in Q2 2026.
- Quarterly Retained Earnings rose 100.12% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 100.12% YoY) and the FY2025 annual result came in at $1.3 billion, up 180.8% from the prior year.
- Retained Earnings advanced to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.4 billion in Q2 2026 to a low of -$1157.0 billion in Q2 2025.
- A 5-year average of -$129.7 billion and a median of -$2.1 billion in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 180.8% in 2025, down 47368.16% in 2025.
- Tracing ARGX's Retained Earnings over 5 years: stood at -$2.1 billion in 2022, then declined by 13.98% to -$2.4 billion in 2023, then jumped by 34.64% to -$1.6 billion in 2024, then soared by 180.8% to $1.3 billion in 2025, then rose by 10.71% to $1.4 billion in 2026.
- The last three Retained Earnings figures came in at $1.4 billion (Q2 2026), $1.3 billion (Q4 2025), and -$1157.0 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Jun 30, 2025 | -1,156.98 Bn |
| Dec 31, 2024 | -1.57 Bn |
| Jun 30, 2024 | -2.44 Bn |
| Dec 31, 2023 | -2.40 Bn |
| Jun 30, 2023 | -2.23 Bn |
| Dec 31, 2022 | -2.11 Bn |
| Jun 30, 2022 | -1.84 Bn |
| Dec 31, 2021 | -1.40 Bn |
| Jun 30, 2021 | -928.76 Mn |
| Dec 31, 2020 | -1.03 Bn |
| Jun 30, 2020 | -592.81 Mn |
| Dec 31, 2019 | -368.12 Mn |
| Jun 30, 2019 | -241.27 Mn |
| Dec 31, 2018 | -193.58 Mn |
| Jun 30, 2018 | -146.84 Mn |
| Dec 31, 2017 | -118.41 Mn |
| Jun 30, 2017 | 10.31 Mn |
| Dec 31, 2016 | -78.27 Mn |